Impact of HIV Infection and HAART on Serum Lipids in Men

CONTEXT Alterations in serum lipid values have been widely reported among persons infected with human immunodeficiency virus (HIV) type 1 treated with highly active antiretroviral therapy (HAART), but no data have yet been reported on changes from preseroconversion lipid values. OBJECTIVE To describ...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:JAMA : the journal of the American Medical Association 2003-06, Vol.289 (22), p.2978-2982
Hauptverfasser: Riddler, Sharon A, Smit, Ellen, Cole, Stephen R, Li, Rui, Chmiel, Joan S, Dobs, Adrian, Palella, Frank, Visscher, Barbara, Evans, Rhobert, Kingsley, Lawrence A
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 2982
container_issue 22
container_start_page 2978
container_title JAMA : the journal of the American Medical Association
container_volume 289
creator Riddler, Sharon A
Smit, Ellen
Cole, Stephen R
Li, Rui
Chmiel, Joan S
Dobs, Adrian
Palella, Frank
Visscher, Barbara
Evans, Rhobert
Kingsley, Lawrence A
description CONTEXT Alterations in serum lipid values have been widely reported among persons infected with human immunodeficiency virus (HIV) type 1 treated with highly active antiretroviral therapy (HAART), but no data have yet been reported on changes from preseroconversion lipid values. OBJECTIVE To describe changes in serum cholesterol levels associated with HIV infection and antiretroviral medication exposure, and 1-time assessment of triglyceride levels post-HAART initiation. DESIGN, SETTING, AND PARTICIPANTS The Multicenter AIDS Cohort Study, a prospective study in which homosexual and bisexual men were enrolled and from which 50 of 517 HIV seroconverters were drawn for the analysis herein, who later initiated HAART, involving measurements of stored serum samples obtained between 1984 and 2002. MAIN OUTCOME MEASURES Changes in levels of total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), and low-density lipoprotein cholesterol (LDL-C) at 6 time points during an average of 12 years; 1-time assessment of triglyceride levels from the third post-HAART clinic visit. RESULTS Among the 50 men, notable declines in mean serum TC (–30 mg/dL [−0.78 mmol/L]), HDL-C (–12 mg/dL [−0.31 mmol/L]), and LDL-C values (–22 mg/dL [−0.57 mmol/L]) were observed after HIV infection. Following HAART initiation, there were large increases in mean TC and LDL-C values (50 and 21 mg/dL [1.30 and 0.54 mmol/L], respectively); however, the mean changes from the preseroconversion values were 20 mg/dL (0.52 mmol/L) (95% confidence interval [CI], –1 to 41) and –1 mg/dL (−0.03 mmol/L) (95% CI, –25 to 22), respectively. Mean HDL-C remained below baseline levels throughout follow-up. The median value (interquartile range) of triglycerides was 225 mg/dL (2.54 mmol/L) (147-331 mg/dL). CONCLUSIONS Before treatment, HIV infection results in substantial decreases in serum TC, HDL-C, and LDL-C levels. Subsequent HAART initiation is associated with increases in TC and LDL-C but little change in HDL-C. Increases in TC and LDL-C observed after about 3 years of HAART possibly represent a return to preinfection serum lipid levels after accounting for expected age-related changes.
doi_str_mv 10.1001/jama.289.22.2978
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_73358563</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><ama_id>196714</ama_id><sourcerecordid>19234356</sourcerecordid><originalsourceid>FETCH-LOGICAL-a468t-acf3fbe35610565184cb90ab55847632bcbd4697b1ba6b8ef12b7d500abb4bcb3</originalsourceid><addsrcrecordid>eNqF0c1LwzAUAPAgipvTu14kCHprzffHcQx1hYmg02tJ2hQ62nQ27cH_3sgmAy_m8gjvx-N9AHCJUYoRwvcb05qUKJ0SkhIt1RGYYk5VQrlWx2CKkFaJZIpNwFkIGxQfpvIUTDCRWjMkpkBl7dYUA-wquMw-YOYrVwx156HxJVzO569rGD9vrh9buKq3dRlg7eGz8-fgpDJNcBf7OAPvjw_rxTJZvTxli_kqMUyoITFFRSvrKBcYccGxYoXVyFjOFZOCElvYkgktLbZGWOUqTKwsOYrEspikM3C3q7vtu8_RhSFv61C4pjHedWPIJaVccUH_hVgTymIfEd78gZtu7H0cIicY_6xOoIiu92i0rSvzbV-3pv_KfzcXwe0emFCYpuqNL-pwcExJrTCJ7mrn4qkOWS0kZvQbRmKCIQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>211359860</pqid></control><display><type>article</type><title>Impact of HIV Infection and HAART on Serum Lipids in Men</title><source>MEDLINE</source><source>American Medical Association Journals</source><creator>Riddler, Sharon A ; Smit, Ellen ; Cole, Stephen R ; Li, Rui ; Chmiel, Joan S ; Dobs, Adrian ; Palella, Frank ; Visscher, Barbara ; Evans, Rhobert ; Kingsley, Lawrence A</creator><creatorcontrib>Riddler, Sharon A ; Smit, Ellen ; Cole, Stephen R ; Li, Rui ; Chmiel, Joan S ; Dobs, Adrian ; Palella, Frank ; Visscher, Barbara ; Evans, Rhobert ; Kingsley, Lawrence A</creatorcontrib><description>CONTEXT Alterations in serum lipid values have been widely reported among persons infected with human immunodeficiency virus (HIV) type 1 treated with highly active antiretroviral therapy (HAART), but no data have yet been reported on changes from preseroconversion lipid values. OBJECTIVE To describe changes in serum cholesterol levels associated with HIV infection and antiretroviral medication exposure, and 1-time assessment of triglyceride levels post-HAART initiation. DESIGN, SETTING, AND PARTICIPANTS The Multicenter AIDS Cohort Study, a prospective study in which homosexual and bisexual men were enrolled and from which 50 of 517 HIV seroconverters were drawn for the analysis herein, who later initiated HAART, involving measurements of stored serum samples obtained between 1984 and 2002. MAIN OUTCOME MEASURES Changes in levels of total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), and low-density lipoprotein cholesterol (LDL-C) at 6 time points during an average of 12 years; 1-time assessment of triglyceride levels from the third post-HAART clinic visit. RESULTS Among the 50 men, notable declines in mean serum TC (–30 mg/dL [−0.78 mmol/L]), HDL-C (–12 mg/dL [−0.31 mmol/L]), and LDL-C values (–22 mg/dL [−0.57 mmol/L]) were observed after HIV infection. Following HAART initiation, there were large increases in mean TC and LDL-C values (50 and 21 mg/dL [1.30 and 0.54 mmol/L], respectively); however, the mean changes from the preseroconversion values were 20 mg/dL (0.52 mmol/L) (95% confidence interval [CI], –1 to 41) and –1 mg/dL (−0.03 mmol/L) (95% CI, –25 to 22), respectively. Mean HDL-C remained below baseline levels throughout follow-up. The median value (interquartile range) of triglycerides was 225 mg/dL (2.54 mmol/L) (147-331 mg/dL). CONCLUSIONS Before treatment, HIV infection results in substantial decreases in serum TC, HDL-C, and LDL-C levels. Subsequent HAART initiation is associated with increases in TC and LDL-C but little change in HDL-C. Increases in TC and LDL-C observed after about 3 years of HAART possibly represent a return to preinfection serum lipid levels after accounting for expected age-related changes.</description><identifier>ISSN: 0098-7484</identifier><identifier>EISSN: 1538-3598</identifier><identifier>DOI: 10.1001/jama.289.22.2978</identifier><identifier>PMID: 12799406</identifier><identifier>CODEN: JAMAAP</identifier><language>eng</language><publisher>Chicago, IL: American Medical Association</publisher><subject>Adult ; Anti-HIV Agents - pharmacology ; Anti-HIV Agents - therapeutic use ; Antiretroviral Therapy, Highly Active ; Biological and medical sciences ; cholesterol ; Cholesterol, HDL - blood ; Cholesterol, LDL - blood ; Drug toxicity and drugs side effects treatment ; highly active antiretroviral therapy ; HIV ; HIV Infections - blood ; HIV Infections - drug therapy ; HIV Seropositivity - blood ; HIV Seropositivity - drug therapy ; HIV-1 ; Human immunodeficiency virus ; Humans ; Infections ; Lipids ; Lipids - blood ; Male ; Medical sciences ; Men ; Miscellaneous (drug allergy, mutagens, teratogens...) ; Pharmacology. Drug treatments ; Regression Analysis ; triglycerides ; Triglycerides - blood</subject><ispartof>JAMA : the journal of the American Medical Association, 2003-06, Vol.289 (22), p.2978-2982</ispartof><rights>2003 INIST-CNRS</rights><rights>Copyright American Medical Association Jun 11, 2003</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-a468t-acf3fbe35610565184cb90ab55847632bcbd4697b1ba6b8ef12b7d500abb4bcb3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://jamanetwork.com/journals/jama/articlepdf/10.1001/jama.289.22.2978$$EPDF$$P50$$Gama$$H</linktopdf><linktohtml>$$Uhttps://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.289.22.2978$$EHTML$$P50$$Gama$$H</linktohtml><link.rule.ids>64,314,780,784,3331,27915,27916,76250,76253</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=14879812$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/12799406$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Riddler, Sharon A</creatorcontrib><creatorcontrib>Smit, Ellen</creatorcontrib><creatorcontrib>Cole, Stephen R</creatorcontrib><creatorcontrib>Li, Rui</creatorcontrib><creatorcontrib>Chmiel, Joan S</creatorcontrib><creatorcontrib>Dobs, Adrian</creatorcontrib><creatorcontrib>Palella, Frank</creatorcontrib><creatorcontrib>Visscher, Barbara</creatorcontrib><creatorcontrib>Evans, Rhobert</creatorcontrib><creatorcontrib>Kingsley, Lawrence A</creatorcontrib><title>Impact of HIV Infection and HAART on Serum Lipids in Men</title><title>JAMA : the journal of the American Medical Association</title><addtitle>JAMA</addtitle><description>CONTEXT Alterations in serum lipid values have been widely reported among persons infected with human immunodeficiency virus (HIV) type 1 treated with highly active antiretroviral therapy (HAART), but no data have yet been reported on changes from preseroconversion lipid values. OBJECTIVE To describe changes in serum cholesterol levels associated with HIV infection and antiretroviral medication exposure, and 1-time assessment of triglyceride levels post-HAART initiation. DESIGN, SETTING, AND PARTICIPANTS The Multicenter AIDS Cohort Study, a prospective study in which homosexual and bisexual men were enrolled and from which 50 of 517 HIV seroconverters were drawn for the analysis herein, who later initiated HAART, involving measurements of stored serum samples obtained between 1984 and 2002. MAIN OUTCOME MEASURES Changes in levels of total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), and low-density lipoprotein cholesterol (LDL-C) at 6 time points during an average of 12 years; 1-time assessment of triglyceride levels from the third post-HAART clinic visit. RESULTS Among the 50 men, notable declines in mean serum TC (–30 mg/dL [−0.78 mmol/L]), HDL-C (–12 mg/dL [−0.31 mmol/L]), and LDL-C values (–22 mg/dL [−0.57 mmol/L]) were observed after HIV infection. Following HAART initiation, there were large increases in mean TC and LDL-C values (50 and 21 mg/dL [1.30 and 0.54 mmol/L], respectively); however, the mean changes from the preseroconversion values were 20 mg/dL (0.52 mmol/L) (95% confidence interval [CI], –1 to 41) and –1 mg/dL (−0.03 mmol/L) (95% CI, –25 to 22), respectively. Mean HDL-C remained below baseline levels throughout follow-up. The median value (interquartile range) of triglycerides was 225 mg/dL (2.54 mmol/L) (147-331 mg/dL). CONCLUSIONS Before treatment, HIV infection results in substantial decreases in serum TC, HDL-C, and LDL-C levels. Subsequent HAART initiation is associated with increases in TC and LDL-C but little change in HDL-C. Increases in TC and LDL-C observed after about 3 years of HAART possibly represent a return to preinfection serum lipid levels after accounting for expected age-related changes.</description><subject>Adult</subject><subject>Anti-HIV Agents - pharmacology</subject><subject>Anti-HIV Agents - therapeutic use</subject><subject>Antiretroviral Therapy, Highly Active</subject><subject>Biological and medical sciences</subject><subject>cholesterol</subject><subject>Cholesterol, HDL - blood</subject><subject>Cholesterol, LDL - blood</subject><subject>Drug toxicity and drugs side effects treatment</subject><subject>highly active antiretroviral therapy</subject><subject>HIV</subject><subject>HIV Infections - blood</subject><subject>HIV Infections - drug therapy</subject><subject>HIV Seropositivity - blood</subject><subject>HIV Seropositivity - drug therapy</subject><subject>HIV-1</subject><subject>Human immunodeficiency virus</subject><subject>Humans</subject><subject>Infections</subject><subject>Lipids</subject><subject>Lipids - blood</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Men</subject><subject>Miscellaneous (drug allergy, mutagens, teratogens...)</subject><subject>Pharmacology. Drug treatments</subject><subject>Regression Analysis</subject><subject>triglycerides</subject><subject>Triglycerides - blood</subject><issn>0098-7484</issn><issn>1538-3598</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2003</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqF0c1LwzAUAPAgipvTu14kCHprzffHcQx1hYmg02tJ2hQ62nQ27cH_3sgmAy_m8gjvx-N9AHCJUYoRwvcb05qUKJ0SkhIt1RGYYk5VQrlWx2CKkFaJZIpNwFkIGxQfpvIUTDCRWjMkpkBl7dYUA-wquMw-YOYrVwx156HxJVzO569rGD9vrh9buKq3dRlg7eGz8-fgpDJNcBf7OAPvjw_rxTJZvTxli_kqMUyoITFFRSvrKBcYccGxYoXVyFjOFZOCElvYkgktLbZGWOUqTKwsOYrEspikM3C3q7vtu8_RhSFv61C4pjHedWPIJaVccUH_hVgTymIfEd78gZtu7H0cIicY_6xOoIiu92i0rSvzbV-3pv_KfzcXwe0emFCYpuqNL-pwcExJrTCJ7mrn4qkOWS0kZvQbRmKCIQ</recordid><startdate>20030611</startdate><enddate>20030611</enddate><creator>Riddler, Sharon A</creator><creator>Smit, Ellen</creator><creator>Cole, Stephen R</creator><creator>Li, Rui</creator><creator>Chmiel, Joan S</creator><creator>Dobs, Adrian</creator><creator>Palella, Frank</creator><creator>Visscher, Barbara</creator><creator>Evans, Rhobert</creator><creator>Kingsley, Lawrence A</creator><general>American Medical Association</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7QL</scope><scope>7QP</scope><scope>7TK</scope><scope>7TS</scope><scope>7U7</scope><scope>7U9</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>H94</scope><scope>K9.</scope><scope>M7N</scope><scope>NAPCQ</scope><scope>P64</scope><scope>RC3</scope><scope>7X8</scope></search><sort><creationdate>20030611</creationdate><title>Impact of HIV Infection and HAART on Serum Lipids in Men</title><author>Riddler, Sharon A ; Smit, Ellen ; Cole, Stephen R ; Li, Rui ; Chmiel, Joan S ; Dobs, Adrian ; Palella, Frank ; Visscher, Barbara ; Evans, Rhobert ; Kingsley, Lawrence A</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-a468t-acf3fbe35610565184cb90ab55847632bcbd4697b1ba6b8ef12b7d500abb4bcb3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2003</creationdate><topic>Adult</topic><topic>Anti-HIV Agents - pharmacology</topic><topic>Anti-HIV Agents - therapeutic use</topic><topic>Antiretroviral Therapy, Highly Active</topic><topic>Biological and medical sciences</topic><topic>cholesterol</topic><topic>Cholesterol, HDL - blood</topic><topic>Cholesterol, LDL - blood</topic><topic>Drug toxicity and drugs side effects treatment</topic><topic>highly active antiretroviral therapy</topic><topic>HIV</topic><topic>HIV Infections - blood</topic><topic>HIV Infections - drug therapy</topic><topic>HIV Seropositivity - blood</topic><topic>HIV Seropositivity - drug therapy</topic><topic>HIV-1</topic><topic>Human immunodeficiency virus</topic><topic>Humans</topic><topic>Infections</topic><topic>Lipids</topic><topic>Lipids - blood</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Men</topic><topic>Miscellaneous (drug allergy, mutagens, teratogens...)</topic><topic>Pharmacology. Drug treatments</topic><topic>Regression Analysis</topic><topic>triglycerides</topic><topic>Triglycerides - blood</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Riddler, Sharon A</creatorcontrib><creatorcontrib>Smit, Ellen</creatorcontrib><creatorcontrib>Cole, Stephen R</creatorcontrib><creatorcontrib>Li, Rui</creatorcontrib><creatorcontrib>Chmiel, Joan S</creatorcontrib><creatorcontrib>Dobs, Adrian</creatorcontrib><creatorcontrib>Palella, Frank</creatorcontrib><creatorcontrib>Visscher, Barbara</creatorcontrib><creatorcontrib>Evans, Rhobert</creatorcontrib><creatorcontrib>Kingsley, Lawrence A</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Calcium &amp; Calcified Tissue Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Physical Education Index</collection><collection>Toxicology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>JAMA : the journal of the American Medical Association</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Riddler, Sharon A</au><au>Smit, Ellen</au><au>Cole, Stephen R</au><au>Li, Rui</au><au>Chmiel, Joan S</au><au>Dobs, Adrian</au><au>Palella, Frank</au><au>Visscher, Barbara</au><au>Evans, Rhobert</au><au>Kingsley, Lawrence A</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Impact of HIV Infection and HAART on Serum Lipids in Men</atitle><jtitle>JAMA : the journal of the American Medical Association</jtitle><addtitle>JAMA</addtitle><date>2003-06-11</date><risdate>2003</risdate><volume>289</volume><issue>22</issue><spage>2978</spage><epage>2982</epage><pages>2978-2982</pages><issn>0098-7484</issn><eissn>1538-3598</eissn><coden>JAMAAP</coden><abstract>CONTEXT Alterations in serum lipid values have been widely reported among persons infected with human immunodeficiency virus (HIV) type 1 treated with highly active antiretroviral therapy (HAART), but no data have yet been reported on changes from preseroconversion lipid values. OBJECTIVE To describe changes in serum cholesterol levels associated with HIV infection and antiretroviral medication exposure, and 1-time assessment of triglyceride levels post-HAART initiation. DESIGN, SETTING, AND PARTICIPANTS The Multicenter AIDS Cohort Study, a prospective study in which homosexual and bisexual men were enrolled and from which 50 of 517 HIV seroconverters were drawn for the analysis herein, who later initiated HAART, involving measurements of stored serum samples obtained between 1984 and 2002. MAIN OUTCOME MEASURES Changes in levels of total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), and low-density lipoprotein cholesterol (LDL-C) at 6 time points during an average of 12 years; 1-time assessment of triglyceride levels from the third post-HAART clinic visit. RESULTS Among the 50 men, notable declines in mean serum TC (–30 mg/dL [−0.78 mmol/L]), HDL-C (–12 mg/dL [−0.31 mmol/L]), and LDL-C values (–22 mg/dL [−0.57 mmol/L]) were observed after HIV infection. Following HAART initiation, there were large increases in mean TC and LDL-C values (50 and 21 mg/dL [1.30 and 0.54 mmol/L], respectively); however, the mean changes from the preseroconversion values were 20 mg/dL (0.52 mmol/L) (95% confidence interval [CI], –1 to 41) and –1 mg/dL (−0.03 mmol/L) (95% CI, –25 to 22), respectively. Mean HDL-C remained below baseline levels throughout follow-up. The median value (interquartile range) of triglycerides was 225 mg/dL (2.54 mmol/L) (147-331 mg/dL). CONCLUSIONS Before treatment, HIV infection results in substantial decreases in serum TC, HDL-C, and LDL-C levels. Subsequent HAART initiation is associated with increases in TC and LDL-C but little change in HDL-C. Increases in TC and LDL-C observed after about 3 years of HAART possibly represent a return to preinfection serum lipid levels after accounting for expected age-related changes.</abstract><cop>Chicago, IL</cop><pub>American Medical Association</pub><pmid>12799406</pmid><doi>10.1001/jama.289.22.2978</doi><tpages>5</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0098-7484
ispartof JAMA : the journal of the American Medical Association, 2003-06, Vol.289 (22), p.2978-2982
issn 0098-7484
1538-3598
language eng
recordid cdi_proquest_miscellaneous_73358563
source MEDLINE; American Medical Association Journals
subjects Adult
Anti-HIV Agents - pharmacology
Anti-HIV Agents - therapeutic use
Antiretroviral Therapy, Highly Active
Biological and medical sciences
cholesterol
Cholesterol, HDL - blood
Cholesterol, LDL - blood
Drug toxicity and drugs side effects treatment
highly active antiretroviral therapy
HIV
HIV Infections - blood
HIV Infections - drug therapy
HIV Seropositivity - blood
HIV Seropositivity - drug therapy
HIV-1
Human immunodeficiency virus
Humans
Infections
Lipids
Lipids - blood
Male
Medical sciences
Men
Miscellaneous (drug allergy, mutagens, teratogens...)
Pharmacology. Drug treatments
Regression Analysis
triglycerides
Triglycerides - blood
title Impact of HIV Infection and HAART on Serum Lipids in Men
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-14T18%3A55%3A49IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Impact%20of%20HIV%20Infection%20and%20HAART%20on%20Serum%20Lipids%20in%20Men&rft.jtitle=JAMA%20:%20the%20journal%20of%20the%20American%20Medical%20Association&rft.au=Riddler,%20Sharon%20A&rft.date=2003-06-11&rft.volume=289&rft.issue=22&rft.spage=2978&rft.epage=2982&rft.pages=2978-2982&rft.issn=0098-7484&rft.eissn=1538-3598&rft.coden=JAMAAP&rft_id=info:doi/10.1001/jama.289.22.2978&rft_dat=%3Cproquest_pubme%3E19234356%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=211359860&rft_id=info:pmid/12799406&rft_ama_id=196714&rfr_iscdi=true